Back to News
Market Impact: 0.42

Roivant Reports Positive Phase 2 Results For Mosliciguat In PH-ILD; Stock Up 17%

Source: Nasdaq

Healthcare & Biotech

Roivant reported that its Phase 2 PHocus trial of mosliciguat met both primary and secondary endpoints in adults with pulmonary hypertension associated with interstitial lung disease. The positive mid-stage clinical outcome de-risks the program and could support further development in an underserved indication.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

moderately positive

Sentiment Score

0.58

Ticker Sentiment

ROIV0.82

More News